Novo Nordisk Aktie

100,50EUR
+1,75EUR
+1,77%
27.05.2022
98,30EUR
-0,62EUR
-0,63%
27.05.2022

WKN: A1XA8R / ISIN: DK0060534915

  Kaufen  
Verkaufen
oder
Werbung

Novo Nordisk Aktien News

06.05.22Novo Nordisk A/S: (GlobeNewswire)
02.05.22Novo Nordisk – major shareholder announcement (GlobeNewswire)
29.04.22Novo Nordisk A/S – Total number of voting rights and share capital in Novo Nordisk A/S as of 29 April 2022 (GlobeNewswire)
29.04.22Novo Nordisk's sales increased by 24% in Danish kroner and by 18% at constant exchange rates to DKK 42.0 billion in the first three months of 2022 (GlobeNewswire)
29.04.22Novo Nordisk's sales increased by 24% in Danish kroner and by 18% at constant exchange rates to DKK 42.0 billion in the first three months of 2022 (GlobeNewswire)
28.04.22Once-weekly insulin icodec demonstrates superior reduction in HbA1c vs insulin degludec in people with type 2 diabetes in ONWARDS 2 phase 3a trial (GlobeNewswire)
27.04.22Novo Nordisk A/S – Reduction of the share capital (GlobeNewswire)
22.04.22Novo Nordisk Indonesia takes a holistic approach to achieve zero environmental impact (PR Newswire)
28.03.22Ozempic® 2.0 mg approved in the US for the treatment of type 2 diabetes (GlobeNewswire)
24.03.22Resolutions from the Annual General Meeting of Novo Nordisk A/S (GlobeNewswire)
14.03.22Novo Nordisk – major shareholder announcement (GlobeNewswire)
04.03.22Novo Nordisk – major shareholder announcement (GlobeNewswire)
03.03.22Highlights to be presented at Novo Nordisk’s Capital Markets Day 2022 (GlobeNewswire)
28.02.22Election of employee representatives to the Board of Directors of Novo Nordisk A/S (GlobeNewswire)
21.02.22Novo Nordisk – major shareholder announcement (GlobeNewswire)
21.02.22Notice for the Annual General Meeting of Novo Nordisk A/S (GlobeNewswire)
14.02.22Novo Nordisk – major shareholder announcement (GlobeNewswire)
02.02.22Novo Nordisk hebt die Dividende das 24. Jahr in Folge an (MyDividends)
02.02.22Novo Nordisk's sales increased by 11% in Danish kroner and by 14% at constant exchange rates to DKK 140.8 billion in 2021 (GlobeNewswire)
14.01.22Novo Nordisk announces settlement of securities lawsuit in Denmark (GlobeNewswire)
17.12.21Novo Nordisk announces supply challenges for Wegovy® in the US (GlobeNewswire)
14.12.21DICERNA INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Dicerna Pharmaceuticals, Inc. - DRNA (PR Newswire)
26.11.21Novo Nordisk announces impact from Volume Based Procurement for insulin in China (GlobeNewswire)
20.11.21DICERNA INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Dicerna Pharmaceuticals, Inc. - DRNA (PR Newswire)
12.11.21Ozempic® 2.0 mg recommended for approval for the treatment of type 2 diabetes by the European Medicines Agency (GlobeNewswire)
11.11.21Wegovy™ recommended for approval for the treatment of obesity by the European regulatory authorities (GlobeNewswire)
05.11.21Wegovy™ demonstrated significant and sustained weight loss in two-year study in adults with obesity (PR Newswire)
03.11.21Novo Nordisk's net profit increased by 12% in the first nine months of 2021 (GlobeNewswire)
29.10.21Novo Nordisk raises sales and operating profit outlook for 2021 (GlobeNewswire)
04.08.21Novo Nordisk's net profit increased by 10% in the first six months of 2021 (GlobeNewswire)
04.08.21Novo Nordisk's net profit increased by 10% in the first six months of 2021 (GlobeNewswire)
28.06.21Novo Nordisk veröffentlicht Zwischenmeldung zum Aktienrückkaufprogramm (MyDividends)
26.06.21Investigational 2.0 mg dose of Ozempic® (semaglutide) demonstrates superior reductions in blood sugar vs Ozempic® 1.0 mg in adults with type 2 diabetes in a phase 3 trial (GlobeNewswire)
04.06.21Wegovy™ (semaglutide 2.4 mg), the first and only once-weekly GLP-1 therapy for weight management, approved in the US (GlobeNewswire)
28.05.21Novo Nordisk resubmits once-weekly semaglutide 2.0 mg for the treatment of type 2 diabetes for US regulatory approval (GlobeNewswire)
07.05.21Novo Nordisk A/S – Share repurchase programme (GlobeNewswire)
07.05.21Novo Nordisk A/S purchases B shares worth DKK 2,586 million from Novo Holdings A/S under the 2021 share repurchase programme (GlobeNewswire)
05.05.21Novo Nordisk's net profit increased by 6% in the first three months of 2021 (GlobeNewswire)
27.04.21Novo Nordisk A/S – Reduction of the share capital (GlobeNewswire)
21.04.21Novo Nordisk to initiate phase 3a development in obesity with oral semaglutide (GlobeNewswire)
Seite: 123

Novo Nordisk News

Novo Nordisk News: auf dieser Seite finden Sie alle Novo Nordisk News und Nachrichten zur Novo Nordisk Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Novo Nordisk News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Novo Nordisk News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.
Werbung
finanzen.net zero
finanzen.net zero

Oskar

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.
Zur klassischen Ansicht wechseln